Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Don’t think this one will ever achieve ‘blue sky’ status due to its simple hoovering up of developed products. Having said that, they don’t have the usual expense/problem/worries of introducing a drug to market. So, with a reasonable dividend, and potential growth/adoption of further drugs, what’s not to like. I'm in...
A few reasonable buys have gone through today , but the low volumes of trades may be why there is not much interest .
This share seems to be a great opportunity but nobody is posting. Trading for the first quarter is up by 6% , their best product sales are up by 14% , they have a lot in the pipeline and a good track record . All the other fundamentals feel good as well . Am I missing something here ? Not invested yet , but think I will in light of anything to the contrary?
CEO John Dawson to present on 23rd April at the Chesterfield Mayfair. Click here to register; http://tinyurl.com/ndxk35e
We are still a month out from the prelims and no holding thresholds have been crossed...yet. Maybe someone has been raiding the drugs cabinet.
Finally a bit of movement here, I wonder why? Anybody out there with any ideas
wow all the cobwebs,i am at qpp.regards.
This share does not soar. It is static. Range is 30-35p and has been since Warren Buffett was a boy...I'm only holding on to it because of IHT (long story) and it pays a dividend. Other than that it is the most boring share I have. Please prove me wrong....
how come noBODY is ere. an article stating aph will soar. Possibly in very long term though. http://www.dianomioffers.co.uk/uploads/product_3842_pdf_link.pdf
What happened?
hmmm......
movement..?....
Todays "tom tip" in the share of the day email...
Yes hard to understand Daierasa but we will see what tomorrow brings :-)
up 9.43% since 13/8. Yet so quiet?
For anyone who is interested : http://www.alliancepharma.co.uk/alliance/dlibrary/panda/Alliance%20Pharma%20Jul13.pdf
We know from the RNS on 11th July that trading in the first half of the year is in line with management's expectations which should be confirmed very soon when the interims are released......so no big surprises coming there then. So providing the second half of the year follows that which we should get some hint of at the time of the interims I would expect. Then we should be looking at a EPS of something like 3.7p taken from Hardman's report. So based on that we should still have a fair upside from here......in my opinion north of 40p. Then of course we should keep in mind : "Alliance continues to explore a number of acquisition opportunities and remains confident of the outlook for the full year." Whether the BOD will have anything for us on that front at the interims remains to be seen.
agree excellent company, got in at 31p only regret not trusting MOR more. Would recommedn a buy, if COMS or EVO come good and I profit take going here
Edging up again today......just 1-2% a day but it is all adding up :-)
Still slowly but steady heading on up :-)
I'm quite amazed at the lack of interest in this well run company which has a proven business plan which has consistently grown over the years and pays a dividend which is unusual for an AIM company and of course now ISAble !
Alliance Pharma wants to do 'more of the same' after Novartis deal John Dawson, CEO of Alliance Pharma (LON:APH), explains to Proactiveinvestors that, after having cemented the deal to acquire 100% of the obstetric drug Syntometrine from Swiss giant Novartis, it is his intention to do 'more of the same' to continue to grow the company. John says that the deal adds extra volume, extra sales, extra margins and flows down to profit ' very nicely'. The deal also takes APH into new territories. http://www.proactiveinvestors.co.uk/companies/stocktube/2035/alliance-pharma-wants-to-do-more-of-the-same-after-novartis-deal--2035.html
Solid looking results. Finncap were looking for EPS of 3p this year 2012 and 3.6p year ending 2013 therefore company are 1 year ahead on expected profits. Dividend risen aswel 10%...excelent news. http://www.investegate.co.uk/alliance-pharma-plc--aph-/rns/preliminary-results/201303210700265097A/
APH Alliance Pharma. Results on the 21st of this month. Thursday. Think profits will beat broker forecast.. just added.
APH Not far off breaking out. BUY placed on it by SCSW tip sheet this weekend. Personaly Im looking for a bolt on before results on 21st of March... see historical item below..... Alliance Pharma gets more ammo for acquisition drive 15th Jan 2013, 1:16 pm by Philip Whiterow Alliance has £13.5mln to spend following the latest injection of funds. Alliance Pharma's (LON:APH) expansion of its acquisition fund is a key development for the specialist pharmaceutical company, according to broker Numis. The group today announced an additional £10mln facility with Lloyds Banking Group, taking the total facility available to the group to make purchases up to £30mln. Alliance has used £16.5mln of the facility and has £13.5mln to spend following the latest injection of funds. Numis said that management has executed on 23 deals over the last 14 years and continually reiterates the strength of its M&A pipeline. If the £13.5mln was fully deployed on acquisitions through 2013 at the historical average 3 times gross profit, the broker sees up to 30% upside to its 2014 profit forecasts. “P/E multiples in the speciality pharma/generics peer group have expanded one point to 12x over the last couple of months - we therefore increase our price target to 42p, from 37p and reiterate our buy rating,” said Numis. Alliance also said profits will beat market forecasts for the year just ended after very strong sales of skin and eczema emollient Hydromol. “As a result of a stronger than expected gross margin rate, pre-tax profits are expected to be slightly ahead of current market expectations,“ the specialist pharmaceutical group said. Total revenues in 2012 will be £44.9mln, compared to £46mln in the previous year. Sales were hit by Sanofi Pasteur’s temporary suspension of the manufacture of Immucyst in June, but Hydromol’s record performance offset some of the impact. Hydromol sales grew by 29% or £1.1 mln to £4.7 mln. Last year’s acquisitions, Opus Group and three anti-malarial brands, performed as expected, Alliance Pharma said. Numis also raised its 2012 profit forecast to £10.5mln, from £10.2mln, following the update. The company’s business model is to acquire the rights to established niche pharmaceutical products. It now owns or licenses the rights to more than 60 products. Shares rose by 4% to 33.5p. http://www.proactiveinvestors.co.uk/companies/news/52444/alliance-pharma-gets-more-ammo-for-acquisition-drive-52444.html